Entera Bio Ltd (ENTX) Stock Analysis
Verdict: HOLD
High-volume clinical breakout on preclinical EB612 results creates a tactical entry window, though 12-month cash runway limits long-term holding.
Investment score: 64/100
Analysis as of
Is Entera Bio Ltd stock worth reviewing? The TradeMates thesis
Entera Bio is a high-risk, high-reward clinical biotech with a strong recent technical breakout backed by positive preclinical data.
7-factor investment score
- Valuation: 40/100 (weight 20%)
- Financial Health: 45/100 (weight 15%)
- Technical Momentum: 85/100 (weight 15%)
- Earnings Quality: 75/100 (weight 15%)
- Insider Sentiment: 50/100 (weight 10%)
- Analyst Consensus: 90/100 (weight 10%)
- Risk-Adjusted Return: 55/100 (weight 15%)
Entera Bio Ltd opportunities and risks
What speaks for ENTX
- Positive EB612 Preclinical Results
What speaks against ENTX
- Immediate Dilution Risk
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| ENTX | n/a | 0.0x | n/a | 0.0% | 0.0% | -10.7% |
| CGEN | 5.7x | 2.7x | 5.4x | 88.1% | 48.0% | 0.0% |
| ENLV | 0.0x | 0.0x | n/a | 0.0% | 0.0% | -76.1% |
| Peer median | 2.9x | 1.4x | 2.2x | 44.0% | 24.0% | -38.1% |
Frequently asked questions about Entera Bio Ltd (ENTX)
Is ENTX stock a good investment?
The TradeMates model rates Entera Bio Ltd as HOLD with an investment score of 64/100. Entera Bio is a high-risk, high-reward clinical biotech with a strong recent technical breakout backed by positive preclinical data. This is algorithmic model output, not personal investment advice.
Is ENTX stock a buy?
The TradeMates model verdict for ENTX is HOLD with an investment score of 64/100. Treat this as a model signal to review, not a personal buy recommendation.